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Abstract
Severe acute respiratory syndrome coronavirus‐2 (SARS CoV‐2) is the causative
agent of the coronavirus disease‐2019 (COVID‐19) pandemic. Coronaviruses enter
cells via fusion of the viral envelope with the plasma membrane and/or via fusion of
the viral envelope with endosomal membranes after virion endocytosis. The spike (S)
glycoprotein is a major determinant of virus infectivity. Herein, we show that the
transient expression of the SARS CoV‐2 S glycoprotein in Vero cells caused extensive cell fusion (formation of syncytia) in comparison to limited cell fusion caused
by the SARS S glycoprotein. Both S glycoproteins were detected intracellularly and
on transfected Vero cell surfaces. These results are in agreement with published
pathology observations of extensive syncytia formation in lung tissues of patients
with COVID‐19. These results suggest that SARS CoV‐2 is able to spread from cell‐
to‐cell much more efficiently than SARS effectively avoiding extracellular neutralizing antibodies. A systematic screening of several drugs including cardiac gly-
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cosides and kinase inhibitors and inhibitors of human immunodeficiency virus (HIV)
entry revealed that only the FDA‐approved HIV protease inhibitor, nelfinavir mesylate (Viracept) drastically inhibited S‐n‐ and S‐o‐mediated cell fusion with complete inhibition at a 10‐μM concentration. In‐silico docking experiments suggested
the possibility that nelfinavir may bind inside the S trimer structure, proximal to the
S2 amino terminus directly inhibiting S‐n‐ and S‐o‐mediated membrane fusion. Also,
it is possible that nelfinavir may act to inhibit S proteolytic processing within cells.
These results warrant further investigations of the potential of nelfinavir mesylate
to inhibit virus spread at early times after SARS CoV‐2 symptoms appear.
KEYWORDS

antiviral agents, cell fusion, cellular effect, coronavirus, entry inhibitors, fusion protein,
glycoproteins, infection, SARS coronavirus, virus classification
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1 | INTRODUCTION

ET AL.

been demonstrated that the RBD domain of SARS CoV‐2 Spike (S‐new;
Sn) has a higher binding affinity for the ACE2 receptor than that of SARS

The severe acute respiratory syndrome coronavirus‐2 (SARS CoV‐2) is

Spike (S‐old; So), while the S2 proteins of these two viruses are nearly

currently associated with a global pandemic causing coronavirus dis-

90% identical.3,22,23

ease, first noted in December 2019 in Wuhan province of China. The

Nelfinavir mesylate was developed as an anti–human im-

resultant disease is termed COVID‐19 (coronavirus disease‐2019) and

munodeficiency virus (HIV) protease inhibitor.24,25 Also, it was re-

is characterized by acute respiratory disease and pneumonia. SARS

ported that nelfinavir mesylate inhibited SARS replication and

CoV‐2 has infected nearly 4 million people and caused nearly 300 000

cytopathic effects in cell culture.26 In addition to its potent activity

deaths worldwide with a predilection of older people and/or people

against the HIV protease, nelfinavir mesylate was found to produce

having other health issues including, hypertension, diabetes, obesity,

multiple effects on cellular processes including the induction of

1‐3

SARSCoV‐2 is the third human coronavirus

apoptosis and necrosis as well as induction of cell‐protective me-

that appeared for the first time in the 21st century. One of the other

chanisms, including cell cycle retardation and the unfolded protein

two coronaviruses is SARS, which appeared in November 2002 in

response.27‐29 These nelfinavir mesylate effects have been exploited

China and caused nearly 100 000 infections worldwide and more than

for anticancer purposes.30‐32

and other comorbidities.

800 deaths. SARS was effectively contained because the virus, al-

Previously, we investigated the structure and function of the

though causing high degree of mortality in infected people, was ap-

SARS S glycoprotein in transient transfection‐membrane fusion as-

parently not effectively transmitted from one person to the other.4,5

says.33,34 Based on these initial studies, we undertook screening of a

The second human coronavirus, Middle East Respiratory Syndrome

number of compounds that may inhibit S‐mediated fusion after tran-

Coronavirus (MERS CoV) appeared in 2013 and caused a limited

sient expression in African green monkey kidney cells (Vero). We re-

epidemic of few thousand people, but high death rates of approxi-

port herein that the SARS CoV‐2 S (Sn) causes extreme S‐mediated

mately 36% predominantly in the Middle East (Saudi Arabia). The

membrane fusion in comparison to cell fusion caused by transient

primary source of infection was found to be dromedary camels, al-

expression of SARS S (So). Importantly, we report that nelfinavir me-

though the virus was transmitted from person to person in close

sylate inhibited S‐mediated fusion at micromolar ranges. In‐silico

6‐9

contact in hospital settings.

docking experiments, revealed the possibility that nelfinavir binds to

All coronaviruses specify a spike (S) glycoprotein, which is em-

the S2 amino terminus within the S trimer and thus, may directly

bedded in viral envelopes in trimeric forms giving them their char-

inhibit the formation of the heptad‐repeat complex that causes S‐

acteristic corona structures. The S glycoprotein is a major antigen

mediated membrane fusion. Based on these results, further research

9

responsible for both receptor‐binding and membrane fusion properties.

of nelfinavir's effect in human COVID‐19 patients is warranted.

Angiotensin‐converting enzyme 2 (ACE2) has been identified as the cell
receptor for SARS,10 and also SARS CoV‐2, while other unknown human
receptors may be responsible for its wider infectious spread than SARS.

2 | M A T E R I A L S AN D M E T H O D S

Spike is cleaved into two major components S1 and S2 by cellular proteases. Virus entry into cells is mediated after binding of a receptor‐

2.1 | Cell line

binding domain (RBD) located within the S1 ectodomain. Cleavage of the
S glycoprotein to produce S1 and S2 proteins is mediated by cellular

African green monkey kidney (Vero) cells were maintained in Dul-

proteases at the S1/S2 junction as well as at S2′ site located downstream

becco's modified Eagle's medium (DMEM) with 10% fetal bovine

of the S1/S2 proteolytic cleavage. The fusion of the viral envelope with

serum (FBS) and 2% primocin (Invitrogen, Inc., Carlsbad, CA).

cellular membranes is mediated by the S2 protein that contains a putative fusion peptide region. The mechanism of membrane pore formation that leads to membrane fusion involves the formation of a six‐helix

2.2 | Reagents and antibodies

bundle fusion core by two heptad repeats HR1 and HR2 domains found
in each S monomer forming the initial pore that results in membrane

Nelfinavir mesylate was bought from R&D Systems, Inc (MN) and

fusion.11 The cellular serine protease TMPRSS2 has been implicated in

dimethyl sulfoxide (DMSO) was bought from Sigma, Inc (St Louis, MO).

priming S2′ cleavage, as well as ACE2 cleavage both required for in-

The primary antibodies used were as follows: mouse anti‐MYC antibody

12‐14

Also, the SARS Spike (S)

(Abcam), mouse anti‐FLAG antibody (Abcam). Goat anti‐mouse antibody

glycoprotein can be cleaved by the cellular protease cathepsin L at the

conjugated with horseradish peroxidase (HRP) was used as a secondary

low pH of endosomes, thereby exposing the S2 domain of the spike

antibody. The Vector Nova Red peroxidase (HRP) substrate kit (Vector

protein for membrane fusion.15‐20 Cell surface expression of S mediates

Laboratories, Burlingame, CA) was used for imaging. Goat anti‐mouse

S‐induced cell fusion and the formation of syncytia, which is a

antibody conjugated with Alexa fluorophore 647 and goat anti‐rabbit

phenomenon similar to virus entry, requiring the presence of ACE2.

antibody conjugated with Alexa fluorophore 488 (Invitrogen, Inc.) were

Virus‐induced cell fusion is a mechanism by which the virus can spread

used for immunofluorescence assay. IRDye goat anti‐mouse and goat

from cell‐to‐cell by a pH‐independent mechanism avoiding the extra-

anti‐rabbit antibody (LI‐COR Biotechnology, Lincoln, NE) were used for

itiation of the membrane fusion event.

21,22

cellular space and potentially evading neutralizing antibody.

It has

immunoprecipitation assay.

MUSARRAT
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2.3 | Construction of recombinant spike proteins

2089

et al23 (PDB ID: 6VSB). The trimer structure of the spike protein was
used for docking as protein structure of the spike protein exists

The SARS and SARS CoV‐2 Spike expression plasmids used in the

under dynamic condition while binding to the receptor and fusion to

present study were constructed in a very similar manner. Both S

host cell. Grid for docking was created on the spike protein structure

genes were placed under the control of the human cytomegalovirus

at particular docking site as the center but covering a grid box of 102

(CMV) immediate early promoter and were engineered to contain

or 126Å in X, Y, Z directions from the center of the grid. One grid site

either 3XFLAG or N‐MYC epitope tags at their amino terminal ends,

was created around protease cleavage site S1/S2 and another cov-

respectively. These S‐n and S‐o genes were cloned into p3XFLAG‐

ering the HR1 region of the protein in the trimer (Figure S1). Docking

CMV‐9 (Sigma, MO) and pCMV3‐SP‐N‐MYC (Sino Biological, PA)

calculations were performed using the Lamarckian genetic algorithm

parental vector plasmids, respectively. The S1 subunit of the S‐n

with 150 starting conformations and 10 million energy evaluations.

expression construct contained the same amino terminus up to

Fifty low energy docked structures were used for final analysis.

aa700 (Gly). The N‐terminal domain of the S‐n S2 subunit was en-

Structures within 2 kcal/mol from the lowest energy docked struc-

gineered to be exactly as in S1 containing the N‐MYC tag at its amino

tures were represented as final possible docked structures using

terminus and encompassing the S2 S‐n amino acid sequence

PyMol software (Schrodinger). The lowest energy docked structure

701‐1273.

was bound near the helices of HR1 region with a docking energy of
−10.57 kcal/mol. Although the docking grid was created to cover the
S1/S2 cleavage site, the low energy docked structure of nelfinavir

2.4 | Transient transfection assay

was bound in the pocket between the helices of fusion peptide and
HR1 region and lower part of NTD region (Figure S2). The docking

Vero cells were grown on 24‐well plates and transiently transfected

energy of the nelfinavir bound structure was −9.98 kcal/mol. In the

with either pCMV3‐SP‐N‐MYC (Sn) or p3XFLAG‐CMV‐S (So) using

lowest energy docked conformation, the nelfinavir‐ SARS CoV‐2

lipofectamine 2000 reagent. Approximately, 2 μL of lipofectamine

spike complex was stabilized by three hydrogen bonds and hydro-

and 0.5 μg of plasmid DNA was used for transfection of Vero cells.

phobic interactions. T768 from S protein fusion peptide formed two

Appropriate controls were also used. Following 48 hours, the plates

hydrogen bonds and Q957 of HR1 helix formed one hydrogen bond

were examined by phase contrast microscopy for fused cells and

with nelfinavir. Hydrophobic interaction was dominated by aromatic

images were taken under live conditions, as well as either after for-

functional groups of nelfinavir with Tyr313, Leu303, and Q314 side

malin or methanol fixation. Cells were stained for FLAG (So, mouse

chains alkyl group in the S protein (Figure S2).

anti‐FLAG‐1:2500) or N‐MYC (Sn, mouse anti‐MYC‐1:500) with HRP
(Vector Nova Red stain kit) for phase contrast microscopy. Similarly,
cells were stained for fluorescent microscopy using anti‐mouse an-

2.7 | Instruments and software

tibody conjugated with Alexa fluorophore 647 (1:100) and anti‐rabbit
antibody conjugated with Alexa fluorophore 488 (1:100).

Olympus IX71 fluorescent microscope was used for live and phase
contrast images using Cellsens software. Zeiss Axio Observer Z1
fluorescent microscope was used for fluorescent images using Zen

2.5 | Drug inhibition of cell fusion assay

software.

Nelfinavir mesylate was dissolved in DMSO at a 10 mM concentration (stock) and a series of dilutions was made in serum‐free DMEM.

3 | RE SU LTS

Following transfection, 500 μL of nelfinavir mesylate solution was
added to each well. Vero cells transfected with either S‐o or S‐n and
incubated with the drug for 48 hours at 37°C with 5% CO2. The

3.1 | SARS CoV‐2 Spike (Sn) is significantly more
fusogenic than SARS Spike (So)

tissue culture plates were observed for fused cells, and then, phase
contrast and fluorescent images were taken under either formalin or

Virus entry is facilitated by S‐mediated fusion between the viral

methanol fixed conditions.

envelope and either cellular plasma membranes or endosomal
membranes. S‐mediated cell fusion is caused by cell surface expression
of S and it is thought to be a surrogate model of both virus entry and

2.6 | Computational methods

cell fusion. Previously, we reported a detailed analysis of the functional
domains of the SARS Spike (S) glycoprotein that are important for

Docking of the nelfinavir mesylate to the spike protein of SARS

S‐mediated membrane fusion and the formation of multinucleated cells

CoV‐2 was performed using Autodock.35 Crystal structure of

(syncytia)

nelfinavir was obtained from the complex of HIV protease nelfinavir

synthesis, cell surface expression, and endocytosis from cell surfaces

crystal structure from the protein data bank (PDB ID: 2Q64).36

(14, 15). To compare the S‐o‐ vs S‐n‐mediated cell fusion, both genes

Structure of the S protein of SARS CoV‐2 was reported by Wrapp

were cloned into the traexpression vectors as codon‐optimized genes

including

delineation

of

domains

important

for

2090
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carrying a 3XFLAG or N‐MYC epitope tags at their amino

monolayers. Phase contrast microscopy revealed the presence of ex-

termini (Figure 1A,B,E,F). In addition, the S1 and S2 domains of S‐n were

tensive syncytia formation in S‐n, but not S‐o‐transfected cells, while

cloned independently into the transient expression vector pCMV3,

the remaining monolayer of cells did not exhibit any cellular toxicity

encompassing amino acid domains for S1 (aa16‐aa700) and S2 (aa701‐

(Figure 2A). Further examination of transfected Vero cells by im-

aa1273). Both S1 and S2 domains were expressed with an MYC epitope

munofluorescence staining for cellular tubulin (anti‐alpha tubulin anti-

tag at their amino termini (Figure 1C,D). The S1 domain included the

body), nuclei (DAPI), and anti‐N‐MYC and anti‐FLAG antibodies

S1/S2 cleavage site (Figure 1C). Vero cells were transfected with

followed by anti‐mouse fluorescent antibody provided additional sup-

the S‐n‐ or S‐o‐expressing plasmids and were detected at 48 hours

port that untransfected monolayers appeared normal, while S‐n ex-

posttransfection (hpt) using anti‐MYC and anti‐FLAG antibodies in

pression produced large syncytia in contrast to much smaller syncytia

conjunction with secondary antibody linked to horseradish peroxidase

formed after S‐o transient expression (Figure 2B). Co‐expression of S1

(see Section 2). Vero cells were also transfected with plasmid vehicle

and S2 was performed to test whether the Sn‐mediated cell fusion

controls or mock‐transfected. Expression of both S‐n and S‐o was

could be reconstituted by coexpression of both domains. Expression of

readily detected by immunohistochemistry, while there was no signal

either S1, S2, or S1 + S2 domains of S‐n was readily detected by im-

obtained from the Vero mock‐transfected and HRP‐stained control cell

munohistochemistry with the anti‐N‐MYC antibody; however, there

F I G U R E 1 Schematics of spike glycoproteins and recombinant gene constructs. (A) Structure of SARS‐CoV‐2 spike (1273aa) glycoprotein,
showing S1 and S2 domains and the cleavage sites S1/S2 and S2′. (B) Structure of pCMV3‐SP‐N‐MYC (Sn). SARS‐CoV‐2 spike (aa16‐aa1273)
was cloned into plasmid expression vector at Kpnl and Xbal restriction sites. The N‐terminal 15 amino acids were replaced with signal peptide
(SP′) and N‐MYC sequence. (C) Structure of pCMV3‐S1‐N‐MYC (S1‐n). The S1 domain (aa16‐aa700) was cloned into the plasmid expression
vector at Kpnl and Xbal restriction sites. The N‐terminal 15 amino acids were replaced with signal peptide (SP′) and N‐MYC sequence. (D)
Structure of pCMV3‐S2‐N‐MYC (S2‐n). The S2 domain (aa701‐aa1273) was cloned at Kpnl and Xbal restriction sites. The N‐terminal contains
signal peptide (SP′) and N‐MYC sequence. (E) Structure of SARS spike (1255aa) glycoprotein, showing S1 and S2 domains and the cleavage sites
S1/S2 and S2′. (F) Structure of p3XFLAG‐CMV‐S (So). SARS spike was cloned into plasmid expression vector as previously described. FP, fusion
peptide; HR1, heptad repeat 1; HR2, heptad repeat 2; NTD, nontranslated domain; RBD, receptor‐binding domain; SARS CoV, severe acute
respiratory syndrome coronavirus; SP, SARS signal peptide; SP′, signal peptide
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F I G U R E 2 Syncytia formation by S‐n and S‐o. Vero cells were transfected with plasmids expressing either the S‐o or S‐n glycoproteins
tagged with the 3XFLAG and N‐MYC epitopes at their amino termini, respectively. S‐n and S‐o expression was detected with mAbs against the
epitope tags at 48 hours posttransfection and compared to vehicle containing equivalent amount of lipofectamine. Methanol fixed cells were
incubated with mouse anti‐N‐MYC (Sn) (1:500 or 1:50) or mouse anti‐FLAG (So) (1:2500 or 1:200) antibody and stained with either (A) HRP
staining or (B) Alexa fluorophore 647 conjugated goat anti‐mouse secondary antibody (1:1000). Cellular tubulin was stained with rabbit
anti‐alpha tubulin (1:200) and anti‐rabbit secondary antibody conjugated with Alexa fluorophore 488 (1:1000). DAPI was used to stain nuclei of
cells. Phase contrast images were taken at ×10 magnification, whereas the fluorescent images were taken at ×40 magnification.
DAPI, 4′,6‐diamidino‐2‐phenylindole; HRP, horseradish peroxidase; S‐n, S‐new; S‐o, S‐old

was no cell fusion observed at 48 hpt as evidenced by only well‐defined

mesylate. Following 48 hpt, the cells were fixed with methanol and

single cells that were stained with the anti‐MYC antibody (Figure 3), as

stained for either N‐MYC (S‐n) or FLAG (S‐o) to detect S‐n and S‐o

well as at later times (not shown), suggesting that the S1 and S2

expression in transfected cells. Nelfinavir mesylate treatment did

domains have to be part of the entire molecule to be processed cor-

not inhibit overall S‐n and S‐o expression, as evidenced by the ef-

rectly for induction of S‐mediated cell fusion.

ficient expression and detection of both proteins via immunohistochemistry (Figure 4A,B). Both S‐n and S‐o mediated
fusion was significantly inhibited by nelfinavir at a dose‐dependent

3.2 | Nelfinavir drastically inhibits cell‐to‐cell fusion
mediated by S‐n and S‐o without affecting cell surface
expression

manner

with

complete

inhibition

observed

at

the

lowest

effective concentration of 10 μM compared with the untreated
control (Figure 4A,B). To determine the effect of nelfinavir on
the surface expression of spike, we transiently transfected

Transiently transfected Vero cells were treated with either

Vero cells with plasmids expressing either the S‐o or S‐n

DMSO, or a series of dilutions (100‐0.001 μM) of nelfinavir

glycoproteins tagged with the 3XFLAG and N‐MYC epitopes at

2092
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F I G U R E 3 Expression of SARS CoV‐2 spike (Sn) domains. Vero cells were transfected with pCMV3‐SP‐N‐MYC plasmid expressing either the
S1, S2, or S1 + S2 domains of S‐n tagged with the N‐MYC epitopes at their amino termini. Expression was detected with mAbs against the
epitope tags at 48 hours posttransfection and compared to vehicle containing equivalent amount of lipofectamine 2000 reagent. Methanol fixed
cells were incubated with mouse anti‐MYC antibody and stained with HRP staining followed by goat anti‐mouse secondary antibody incubation.
Images were taken at ×10 magnification. HRP, horseradish peroxidase; SARS CoV, severe acute respiratory syndrome coronavirus; Sn, S‐new

their amino termini, respectively, and treated these cells with either

significant differences in the number of fused cells (size of syncytia)

nelfinavir (10 μM) or DMSO control for 48 hours at 37°C with 5%

following drug treatment, no apparent difference was visible in

CO2. The cells were observed for characteristic syncytia formation

the surface expression of spike compared to total spike expression

and then fixed with either formalin or methanol to detect surface

between S‐n‐ and S‐o‐transfected cells. These experiments revealed

expression or endogenous expression of the spike glycoprotein

that nelfinavir at concentrations that drastically inhibited cell fu-

following nelfinavir treatment, respectively. Although there were

sion, did not affect S‐n or S‐o cell surface expression (Figure 5).

F I G U R E 4 Fusion inhibition by nelfinavir. (A) Vero cells were transfected with plasmids expressing either the S‐o or S‐n glycoproteins tagged
with the 3XFLAG and N‐MYC epitopes at their amino termini, respectively. S‐n and S‐o expression was detected with mAbs against the epitope
tags at 48 hours posttransfection and compared to vehicle containing equivalent amount of DMSO. (B) S‐n and S‐o glycoproteins were
expressed as in (A). Nelfinavir was added at the time of transfection at the concentrations indicated. Methanol fixed cells were incubated with
mouse anti‐MYC (S‐n) or mouse anti‐FLAG (S‐o) antibody and stained with HRP staining followed by goat anti‐mouse secondary antibody
incubation. Images were taken at ×10 magnification. HRP, horseradish peroxidase; DMSO, dimethyl sulfoxide; Sn, S‐new; So, S‐old
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3.3 | Computation modeling of nelfinavir—S‐n
potential interactions

2093

producing adverse effects in the infected host. Herein, we show that
the SARS CoV‐2 Spike (Sn) glycoprotein causes drastically more
cell fusion and syncytia formation in comparison to the SARS Spike

Recently, it was shown that a peptide that targeted the S‐n HR1

(So) glycoprotein following transient expression in Vero cells. Im-

domain S inhibited SARS‐CoV‐2 virus replication, virus entry, and

portantly, we show that nelfinavir mesylate, a currently prescribed

virus‐induced cell fusion.37 Therefore, we performed in‐silico docking

anti‐HIV protease inhibitor, drastically inhibited both S‐n‐ and

experiments to investigate the possibility that nelfinavir may directly

S‐o‐mediated cell fusion. These results indicate that it is highly likely

bind near this S region. These theoretical docking experiments

that increased SARS CoV‐2 virulence over SARS may be attributed to

revealed that nelfinavir may bind near the HR1 helix and in between

the enhanced fusogenicity exhibited by S‐n in comparison to the S‐o

the HR1 and HR2 helices (Figures S1 and S2).

glycoprotein. Importantly, the fact the nelfinavir drastically inhibited
S‐n‐ and S‐o‐mediated cell fusion suggests that it should be used as
an anti‐SARS CoV‐2 antiviral, especially at early times after first

4 | D I S C U S SI O N

symptoms are exhibited in infected individuals.
Transient expression of S‐n and S‐o glycoproteins produced

Virus‐induced cell fusion and the formation of multinucleated cells

drastic differences in cell fusion, while their overall protein expression

(syncytia) is the hallmark of many different viral infections including

was similar, as evidenced by immunohistochemistry signals obtained at

retroviruses, herpesviruses, coronaviruses, and other viruses. These

48 hpt. The enhanced fusogenicity of SARS CoV‐2 vs SARS CoV was

membrane fusion phenomena are caused by expression of fusogenic

recently noted in infection of Vero cells,37 further validating that our

glycoproteins on infected cell surfaces. Cell‐to‐cell fusion mediated

transient transfection results reflect spike‐mediated virus‐induced cell

by viral glycoproteins is similar to fusion of viral envelopes with

fusion differences between SARS and SARS CoV‐2. Cell surface ex-

cellular membranes that typically occur at the plasma membrane at

pression of S‐n and S‐o was comparable suggesting that the observed

physiological pH or after endocytosis of virion enveloped particles

differences in membrane fusion was due to inherent differences in

within endosomes followed by fusion of the viral envelope with

the structure and function of S‐n vs S‐o glycoproteins. Interestingly,

endosomal membranes to release the nucleocapsid protein in the

independent expression of S1 and S2 domains of S‐n did not cause any

cytoplasm.38 Virus‐induced cell fusion is an important cytopathic

cell fusion. It is not clear whether these two domains could be pro-

phenomenon because the virus can spread from cell‐to‐cell avoiding

cessed and expressed on cell surfaces, although the S‐2 domain could

extracellular spaces and exposure to neutralizing antibodies.39 Virus‐

be detected via immunohistochemistry (not shown). These results

induced cell fusion can also cause hyperinflammatory responses

suggest that the entire S glycoprotein needs to be expressed in an

F I G U R E 5 Surface expression of spike glycoproteins. Vero cells were transfected with plasmids expressing either the S‐o or S‐n
glycoproteins tagged with the 3XFLAG and N‐MYC epitopes at their amino termini, respectively. S‐n and S‐o expression was detected with
mAbs against the epitope tags at 48 hours posttransfection and compared to vehicle containing equivalent amount of DMSO. Nelfinavir was
added at the time of transfection at the concentrations indicated. Formalin or Methanol fixed cells were incubated with mouse anti‐N‐MYC (Sn)
(1:100) or mouse anti‐FLAG (So) (1:200) antibody and stained with Alexa fluorophore 647 conjugated goat anti‐mouse secondary antibody
(1:1000). Cellular tubulin was stained with rabbit anti‐alpha tubulin (Abcam; 1:200) and anti‐rabbit secondary antibody conjugated with Alexa
fluorophore 488. DAPI was used to stain nuclei of cells. Fluorescent images were taken at ×40 magnification. DAPI, 4′,6‐diamidino‐2‐
phenylindole; DMSO, dimethyl sulfoxide; Sn, S‐new; So, S‐old
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uncleaved form that may be proteolytically processed either within

grants NIH: NIGMS P20 GM103424 (Louisiana Biomedical Research

endosomes or at cell surfaces by proteases such as TMPRSS2, which is

Network) and NIH: NIGMS P20GM130555 (Center for Lung Biology)

12

known to be required for Spike activation during virus entry.

and the School of Veterinary Medicine, Louisiana State University.

We utilized the S‐n and S‐o transient expression system to
screen for currently available drugs that may inhibit S‐mediated

ORCI D

cell fusion and the formation of syncytia. These drugs included cardiac

Konstantin G. Kousoulas
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glycosides such as ouabain and digoxin, the anti‐HIV fusion inhibitor
Fuzeon (enfuvirtide) and kinase inhibitors including Gleevec (imatinib

R E F E R E N CE S

mesylate). These drugs did not substantially inhibit S‐mediated cell
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